Denosumab Versus Zoledronic Acid for Preventing Symptomatic Skeletal Events in Asian Postmenopausal Women With Oestrogen-Receptor-Positive Advanced Breast Cancer: An Outcome Analyses With a Mean Follow-Up of 3 Years

BMC Musculoskeletal Disorders - United Kingdom
doi 10.1186/s12891-018-2338-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2019English

Phase 1b Study of Orteronel in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic Breast Cancer

Investigational New Drugs
OncologyPharmacology
2016English

Breast-Cancer Adjuvant Therapy With Zoledronic Acid

New England Journal of Medicine
Medicine
2012English

Incidence of Hypocalcemia in Patients With Post-Menopausal Osteoporosis or Cancer Skeletal Related Events After Denosumab in Comparison to Zoledronic Acid in a Community Hospital Setting

Journal of Pharmacovigilance
2015English

Oestrogen Receptor Status and Survival in Women With BRCA2-associated Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
2019English

Denosumab and Breast Cancer Risk in Postmenopausal Women: A Population-Based Cohort Study

British Journal of Cancer
Cancer ResearchOncology
2018English

Oestrogen Plus Progestogen Increased Risk of Breast Cancer in Postmenopausal Women

Evidence-Based Medicine
Medicine
2003English

Efficacy of First-Line Letrozole Versus Tamoxifen as a Function of Age in Postmenopausal Women With Advanced Breast Cancer

Oncologist
Cancer ResearchMedicineOncology
2004English

Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy